Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC

Figures & data

Table 1 Combined Small Cell Lung Cancer and Small Cell Lung Cancer Patient Characteristics from SEER Database

Variables	SCLC (%)	C-SCLC (%)	P
Total	20,841 (100)	400 (100)
Age			0.158
< 65	8599 (41.3)	151 (37.8)
≥ 65	12,242 (58.7)	249 (62.3)
Race			0.030
White	17,990 (86.3)	328 (82.0)
Black	1975 (9.5)	53 (13.3)
Others	876 (4.2)	19 (4.8)
Sex			0.018
Female	10,469 (50.2)	177 (44.3)
Male	10,372 (49.8)	223 (55.8)
T stage			< 0.001
T0	266 (1.3)	1 (0.3)
T1	2529 (12.1)	86 (21.5)
T2	5451 (26.2)	115 (28.8)
T3	4542 (21.8)	89 (22.3)
T4	8053 (38.6)	109 (27.3)
N stage			< 0.001
N0	3049 (14.6)	136 (34.0)
N1	1510 (7.2)	34 (8.5)
N2	11,614 (55.7)	160 (40.0)
N3	4668 (22.4)	70 (17.5)
Surgery			< 0.001
Yes	495 (2.4)	106 (26.5)
No	20,346 (97.6)	294 (73.5)
Bone metastasis			< 0.001
Yes	4853 (23.3)	62 (15.5)
No	15,988 (76.7)	338 (84.5)
Brain metastasis			0.008
Yes	3479 (16.7)	47 (11.8)
No	17,362 (83.3)	353 (88.3)
Liver metastasis			< 0.001
Yes	6291 (30.2)	64 (16.0)
No	14,550 (69.8)	336 (84.0)
Lung metastasis			0.291
Yes	2994 (14.4)	50 (12.5)
No	17,847 (85.6)	350 (87.5)

Table 2 Propensity Score Matching Was Conducted Among Small Cell Lung Cancer and Combined Small Cell Lung Cancer Patients

Variables	SCLC (%)	C-SCLC (%)	P
Total	400 (100)	400 (100)
Age			0.714
< 65	146 (36.5)	151 (37.8)
≥ 65	254 (63.5)	249 (62.3)
Race			0.865
White	332 (83.0)	328 (82.0)
Black	52 (13.0)	53 (13.3)
Others	16 (4.0)	19 (4.8)
Sex			0.943
Female	176 (44.0)	177 (44.3)
Male	224 (56.0)	223 (55.8)
T stage			0.999
T0	1 (0.3)	1 (0.3)
T1	83 (20.8)	86 (21.5)
T2	117 (29.3)	115 (28.8)
T3	88 (22.0)	89 (22.3)
T4	111 (27.8)	109 (27.3)
N stage			0.998
N0	136 (34.0)	136 (34.0)
N1	33 (8.3)	34 (8.5)
N2	162 (40.5)	160 (40.0)
N3	69 (17.3)	70 (17.5)
Surgery			< 0.001
Yes	24 (6.0)	106 (26.5)
No	376 (94.0)	294 (73.5)
Bone metastasis
Yes	62 (15.5)	62 (15.5)	1.000
No	338 (84.5)	338 (84.5)
Brain metastasis
Yes	43 (10.8)	47 (11.8)	0.654
No	357 (89.3)	353 (88.3)
Liver metastasis
Yes	64 (16.0)	64 (16.0)	1.000
No	336 (84.0)	336 (84.0)
Lung metastasis			0.663
Yes	46 (11.5)	50 (12.5)
No	354 (88.5)	350 (87.5)

Figure 1 Survival curves for patients with c-SCLC and SCLC before PSM (P < 0.001).

Table 3 Cox Regression Analyses of Prognostic Factors for Overall Survival for Patients with Small Cell Lung Cancer and Combined Small Cell Lung Cancer

Variables	Univariate Analysis		Multivariate Analysis
	Wald χ^2	P	HR (95% CI)	P
Age	368.60	< 0.0001		< 0.0001
< 65			Reference
≥ 65			1.424 (1.380–1.469)	< 0.0001
Race	14.53	0.001		0.011
White
Black			0.941 (0.893–0.991)	0.022
Others			0.922 (0.856–0.995)	0.035
Sex	110.88	< 0.0001		< 0.0001
Female
Male			1.123 (1.090–1.158)	< 0.0001
Cancer type	35.35	< 0.0001		0.411
SCLC
c-SCLC			0.950 (0.842–1.073)	0.411
T stage	312.94	< 0.0001		< 0.0001
T0			Reference
T1			0.926 (0.800–1.073)	0.308
T2			1.169 (1.014–1.348)	0.032
T3			1.217 (1.055–1.405)	0.007
T4			1.243 (1.079–1.433)	0.003
N stage	259.52	< 0.0001		< 0.0001
N0			Reference
N1			0.974 (0.907–1.045)	0.456
N2			1.169 (1.116–1.225)	< 0.0001
N3			1.174 (1.113–1.239)	< 0.0001
Surgery	295.21	< 0.0001		< 0.0001
Yes			Reference
No			1.927 (1.717–2.163)	< 0.0001
Bone metastasis	607.88	< 0.0001		< 0.0001
No			Reference
Yes			1.136 (1.093–1.180)	< 0.0001
Brain metastasis	396.61	< 0.0001		< 0.0001
No			Reference
Yes			1.415 (1.360–1.472)	< 0.0001
Liver metastasis	1829.23	< 0.0001		< 0.0001
No			Reference
Yes			1.789 (1.727–1.854)	< 0.0001
Lung metastasis	459.14	< 0.0001		< 0.0001
No			Reference
Yes			1.232 (1.180–1.286)	< 0.0001

Figure 2 (A) Survival curves for patients with c-SCLC and SCLC after PSM (P = 0.789). (B) Survival curves for c-SCLC and SCLC patients after surgery (P = 0.162).